ELTHYRONE Side Effects

5635070-6 | Rash, Toxic Skin Eruption
on Feb 14, 2008 Female patient from BELGIUM , weighting 176.4 lb, was diagnosed with hypothyroidism and was treated with Elthyrone (View Usage). Patient experienced the following unwanted or unexpected effects: rash (What is rash?), toxic skin eruption. Elthyrone dosage: . During the same period patient was treated with BEFACT (View Befact Review and Befact Label ), MESALAMINE (View Mesalamine Review and Mesalamine Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), TIZANIDINE HYDROCHLORIDE (.5-1.5/day) (View Tizanidine Hydrochloride Review and Tizanidine Hydrochloride Label ), SERTRALINE (View Sertraline Review and Sertraline Label ), LEVOCETIRIZINE (View Levocetirizine Review and Levocetirizine Label ). Patient was hospitalized.

4775040-3 | Aseptic Necrosis Bone, Bone Density Increased, Intestinal Adenocarcinoma, Metastases To Bone, Metastases To Lung
Patient was taking Elthyrone (View Usage). Patient had the following side effects: aseptic necrosis bone, bone density increased, intestinal adenocarcinoma, metastases to bone, metastases to lung on Jun 22, 2005 from BELGIUM Additional patient health information: Female patient , 69 years of age, weighting 156.5 lb, was diagnosed with metastases to bone and. Elthyrone dosage: . During the same period patient was treated with XANAX (View Xanax Review and Xanax Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ), ZOMETA (4 Mg, Qmo) (View Zometa Review and Zometa Label ), AREDIA (30 Mg, Unk) (View Aredia Review and Aredia Label ), CYCLOPHOSPHAMIDE + 5 FU + METHOTREXATE (View Cyclophosphamide + 5-fu + Methotrexate Review and Cyclophosphamide + 5-fu + Methotrexate Label ).

4705502-6 | Aseptic Necrosis Bone, Bone Density Increased, Metastases To Bone, Osteonecrosis
Adverse event was reported on Jun 22, 2005 by a Female patient taking Elthyrone (View Usage) (Dosage: ) was diagnosed with metastases to bone and. Location: BELGIUM , 69 years of age, weighting 156.5 lb, After Elthyrone was administered, patient had the following side effects: aseptic necrosis bone, bone density increased, metastases to bone, osteonecrosis (What is osteonecrosis?). During the same period patient was treated with XANAX (View Xanax Review and Xanax Label ), TEMESTA (View Temesta Review and Temesta Label ), ZOMETA (4 Mg, Qmo) (View Zometa Review and Zometa Label ).

4705486-0 | Aseptic Necrosis Bone, Bone Density Increased, Metastases To Bone
on Jun 22, 2005 Female patient from BELGIUM , 69 years of age, weighting 156.5 lb, was diagnosed with metastases to bone and was treated with Elthyrone (View Usage). Patient experienced the following unwanted or unexpected effects: aseptic necrosis bone, bone density increased, metastases to bone. Elthyrone dosage: . During the same period patient was treated with XANAX (View Xanax Review and Xanax Label ), TEMESTA (View Temesta Review and Temesta Label ), ZOMETA (4 Mg, Qmo) (View Zometa Review and Zometa Label ).


4615023-7 | Blood Creatinine Increased, Blood Phosphorus Increased, Blood Sodium Increased, Blood Thyroid Stimulating Hormone Increased, Hypothyroidism, Thyroxine Abnormal, Tri-iodothyronine Decreased
on Mar 17, 2005 Female patient from , 57 years of age, was diagnosed with nail tinea and was treated with Elthyrone (View Usage). Patient had the following side effects: blood creatinine increased, blood phosphorus increased, blood sodium increased, blood thyroid stimulating hormone increased, hypothyroidism, thyroxine abnormal, tri-iodothyronine decreased. Elthyrone dosage: 112.5 Ug/d. During the same period patient was treated with STEOVIT D3 (2 Df, Qw) (View Steovit D3 Review and Steovit D3 Label ), LAMISIL (250 Mg/d) (View Lamisil Review and Lamisil Label ).